Neuropathic Pain Market Outlook and Opportunities in Grooming Regions with Forecast 2035

Neuropathic Pain Market Outlook and Opportunities in Grooming Regions with Forecast 2035

Rising Geriatric Population and Advancements in Pain Management Therapies to Propel the Global Neuropathic Pain Market at a CAGR of 7.12% during the Forecast Period 2025 to 2035

Market Research Future (MRFR) has published a cooked research report on the “Global Neuropathic Pain Market” that contains information from 2019 to 2035. The Neuropathic Pain Market was valued at USD 7.80 billion in 2024 and is projected to grow from USD 8.35 billion in 2025 to USD 16.62 billion by 2035, exhibiting a CAGR of 7.12% during the forecast period 2025–2035.

MRFR recognizes the following companies as the key players in the Global Neuropathic Pain Market — Pfizer, Merck & Co, AbbVie, Eli Lilly, Boehringer Ingelheim, Johnson & Johnson, Teva Pharmaceutical Industries, Novartis, Celgene, Mylan, Astellas Pharma, NantKwest, GlaxoSmithKline, Amgen, and Sanofi.

Market Highlights

The Global Neuropathic Pain Market is witnessing significant growth due to the rising prevalence of neuropathic pain conditions, particularly diabetic neuropathy, postherpetic neuralgia, and chemotherapy-induced neuropathy, alongside an expanding aging population and advancements in treatment modalities.

The market’s growth is further supported by increased awareness, better diagnostic practices, and a shift toward non-opioid therapies aimed at addressing chronic pain effectively while minimizing addiction risks. According to demographic projections, the global geriatric population aged 65 and above is expected to double by 2050, which will substantially increase the incidence of neuropathic pain cases worldwide.

Furthermore, advancements in personalized medicine, telehealth integration, and regenerative therapies are opening new avenues for targeted treatment, improving patient outcomes, and expanding the global market reach.

Segment Analysis

Based on Type of Neuropathic Pain, the market is segmented into Diabetic Neuropathy, Postherpetic Neuralgia, Trigeminal Neuralgia, and Chemotherapy-Induced Peripheral Neuropathy. Diabetic Neuropathy held the largest share of USD 2.25 billion in 2024 and is projected to reach USD 3.83 billion by 2035, reflecting the global rise in diabetes prevalence. Postherpetic Neuralgia is estimated to increase from USD 1.35 billion in 2024 to USD 2.39 billion by 2035, driven by a higher occurrence of shingles-related nerve damage.

Based on treatment, the market is segmented into Medications, Physical Therapy, Surgical Procedures, and Electrical Stimulation. Medications remain the primary treatment mode due to the availability of drugs like pregabalin and duloxetine that effectively manage neuropathic pain. Physical Therapy is gaining popularity for its non-pharmacological benefits, promoting rehabilitation and long-term pain management.

Based on Route of Administration, the segment includes Oral, Topical, and Injectable routes. Oral administration dominates the market due to its convenience and patient compliance. Topical treatments are gaining traction for offering localized relief with fewer side effects, while injectable formulations are used for severe pain management.

By End User, the segments include Hospitals, Clinics, and Home Care. Hospitals hold the largest share due to advanced diagnostic and therapeutic infrastructure. Home Care is the fastest-growing segment, supported by telemedicine and home-based digital pain management technologies.

Regional Insights

North America leads the global Neuropathic Pain Market with a valuation of USD 2.45 billion in 2024, projected to reach USD 4.1 billion by 2035. The region’s dominance is attributed to a high prevalence of chronic diseases, strong healthcare infrastructure, and robust R&D initiatives by major pharmaceutical firms.

Europe accounted for USD 1.8 billion in 2024 and is expected to reach USD 3.0 billion by 2035. The region benefits from favorable reimbursement policies and growing adoption of multidisciplinary pain management approaches, especially in countries like Germany, France, and the UK.

Asia-Pacific, valued at USD 0.9 billion in 2024, is projected to grow to USD 1.5 billion by 2035, making it one of the fastest-growing regions. Factors such as rising diabetes prevalence, increasing healthcare spending, and growing awareness about neuropathic pain drive regional expansion.

Middle East & Africa is valued at USD 0.19 billion in 2024 and expected to reach USD 0.3 billion by 2035, this region is gradually expanding as healthcare infrastructure strengthens, and awareness initiatives increase.

Key Findings of the Study

• The Global Neuropathic Pain Market is projected to reach USD 16.62 billion by 2035, at a CAGR of 7.12% from 2025 to 2035.


• North America dominates the market, while Asia-Pacific is the fastest-growing region.


• Diabetic Neuropathy remains the leading pain type, while Postherpetic Neuralgia is witnessing rapid growth.


• Medications continue to dominate treatment preferences, supported by increasing development of non-opioid alternatives.


• Astellas Pharma, Novartis, AbbVie, and Pfizer are among the major companies shaping the competitive landscape through R&D and new product launches.


• Emerging opportunities include the integration of digital health solutions, regenerative medicine, and personalized pain therapies.